Category - Executive Moves

Knight Therapeutics

Knight takes stake in 3D Signatures

Knight Therapeutics (TSX:GUD) has closed on a $1-million equity investment in closely-held 3D Signatures, which has completed a business combination and public listing transaction.3D is a personalized medicine company...


Karen Licitra to join Novadaq board

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) said Karen Licitra will be joining the company’s board of directors. Ms. Licitra has a track record of accomplishments in sales, marketing, commercial and general...

Corey Davis joins HCW’s research team

Corey Davis has joined H.C. Wainwright in equity research as a managing director, covering specialty pharmaceuticals.Dr. Davis has 19 years of sell-side experience, covering specialty pharmaceutical companies, spending...


Oramed names Dr. Roy Eldor as CMD

Oramed Pharmaceuticals (NASDAQ:ORMP) appointed Dr. Roy Eldor to the newly created post of chief medical director. “We are very pleased to welcome Dr. Eldor on board at this pivotal time for Oramed as we head towards a...

ProMIS names Johanne Kaplan as CDO

ProMIS Neurosciences (TSX:PMN) has appointed Johanne Kaplan to the post of chief development officer to focus on supporting the design and execution of the company’s development programs and partnering efforts.


Soricimed announces members of CAB

Closely-held Soricimed Biopharma has announced the members of its newly formed Clinical Advisory Board (CAB). The CAB, comprising key thought leaders in the treatment of cancer and novel anti-cancer targets, will...

Merus Labs appoints two senior executives

Merus Labs International (NASDAQ:MSLI; TSX:MSL) has appointed two key additions to its executive leadership team, effective July 1.Dr. Michael Bumby was named CFO, succeeding Andrew Patient, who has decided to leave the...